You are right! It's funny, I haven't checked on this message board for 6 months and of course the first post I see is "the pe is insane" lol just like 6 months and 50 dollars ago
people may be suckers for buying this stock but I wouldn't call this a pos joke......hopefully it's the real deal and helps people with DN, I'm just skeptical
Why then, when the size of the addressable market is in the BILLIONS is the market cap of this company only in the 100million range!!!!???????? Now I know what everyone is going to say....."oh you're short" or "oh look at the scientist involved" well......money talks and bulls#*t walks and until the value/market cap of this company shows investment $$ and confidence not the usual pump then short 55% of the float then dump well............good luck suckers
How come the market cap is so low? Too low for their prospects. Makes me skeptical just for that reason only.
everyone's skeptical, calling it a vitamin, no patent protection etc
sure is interesting if it's all on the up and up
Completed Phase 2 studies have indicated that Pyridorin is effective in inhibiting this important underlying cause of diabetic nephropathy and slowing its progression, with more than an approximately 50% treatment effect demonstrated in patients with mild to moderate levels of disease, and in patients with advanced disease that were previously on an established stable regimen of standard of care.
NephroGenex has established a Special Protocol Assessment (SPA) agreement with the FDA for its Pyridorin Phase 3 PIONEER program. PYR-311, the first of two identical trials, is evaluating the safety and efficacy of Pyridorin in this same patient population utilizing a new endpoint that is expected to reduce trial follow-up time and cost by approximately 50%, compared to previous diabetic nephropathy trials. Pyridorin has also received Fast Track Designation from the FDA for this indication.
Based on results from our previous studies, which indicated efficacy in this patient group, and a well-tolerated safety profile, we believe Pyridorin has great potential to effectively address the critical medical need of progressive nephropathy in type 2 diabetic patients. For more information about our pivotal Phase 3 Pyridorin trial, see clinicaltrials.gov.
"there are people on this board waaaaaaaaaaaaaaay longer than you." And that is relevant why?
"The stock was trading around $12.00 less than a year ago, which is more than a double at this point by my math"
Congrats, you can multiply! Stock price aside, does management have the ability to run this public company efficiently and PROFITABLY? The jury is still out on that imo. Good luck!
super intelligent post there diejour44, when anyone with a slightly larger than pea sized brain can tell I'm not a short lol
"is 100m enough"? Maybe not but without the most recent public offering they already had 200m in cash. Is that enough?
"then to expand the test scope, to cover more for African American population"
I didn't know the current label on the box reads "for caucasians only"
SHOW ME you can run your company efficiently, sell your currently FDA approved and Medicare paid for product and TURN A PROFIT!! TURN A PROFIT!! TURN A PROFIT!! DO YOU UNDERSTAND WHAT I"M SAYING? lol THEN issue a few shares (if you still needed to) AND (probably at a much higher stock price)
If "ifs" and "buts" were candy and nuts........I just feel they're getting ahead of themselves. Everybody says hey! they can take this extra 100m and do this and that, advance this and buy them. Well, EXAS has what seems like the greatest thing since sliced bread so why not refrain for a few yrs from diluting shareholders and just concentrate on selling your currently FDA approved and Medicare paid for product.....rake in 200-300m? By then the stock price might be double what it is today. I just feel doing what they did in the last few days is planning for failure ya know "just in case".
If they can't make it with Colonguard the I doubt I stick around to give them another chance. Surely someone can understand my reasoning?
Yes, but depleted at what rate? 50m per yr? That's a good 3+ yrs worth of cash on hand? I know its cutting it close but, have some confidence and some cahones that your product is going to be successful, like I hear when the ceo does an interview! I guess in today's world we do pre bailouts now right?
200m in cash and a FDA approved medicare paid product selling now but hey, its easier just to dilute shareholders. Isn't 200m enough?